Dose-finding Study for SAR442168 in Relapsing Multiple Sclerosis

NCT03889639 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

130

Enrollment

INDUSTRY

Sponsor class

Conditions

Relapsing Multiple Sclerosis

Interventions

DRUG: SAR442168
DRUG: Placebo
DRUG: Locally approved intravenous contrast medium for contrast enhanced magnetic resonance imaging (MRI)

Sponsor

Sanofi